JP2011506328A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506328A5
JP2011506328A5 JP2010537016A JP2010537016A JP2011506328A5 JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5 JP 2010537016 A JP2010537016 A JP 2010537016A JP 2010537016 A JP2010537016 A JP 2010537016A JP 2011506328 A5 JP2011506328 A5 JP 2011506328A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
composition according
seq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010537016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506328A (ja
JP5520230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/085280 external-priority patent/WO2009076105A2/en
Publication of JP2011506328A publication Critical patent/JP2011506328A/ja
Publication of JP2011506328A5 publication Critical patent/JP2011506328A5/ja
Application granted granted Critical
Publication of JP5520230B2 publication Critical patent/JP5520230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010537016A 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与 Expired - Fee Related JP5520230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99267807P 2007-12-05 2007-12-05
US60/992,678 2007-12-05
PCT/US2008/085280 WO2009076105A2 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (3)

Publication Number Publication Date
JP2011506328A JP2011506328A (ja) 2011-03-03
JP2011506328A5 true JP2011506328A5 (enExample) 2012-02-16
JP5520230B2 JP5520230B2 (ja) 2014-06-11

Family

ID=40756064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537016A Expired - Fee Related JP5520230B2 (ja) 2007-12-05 2008-12-02 内在化ペプチドに連結された薬剤と抗炎症剤との共投与

Country Status (14)

Country Link
US (1) US8080518B2 (enExample)
EP (1) EP2229185B8 (enExample)
JP (1) JP5520230B2 (enExample)
CN (1) CN101970011B (enExample)
AU (1) AU2008335490B2 (enExample)
BR (1) BRPI0820912B1 (enExample)
DK (1) DK2229185T3 (enExample)
ES (1) ES2555524T3 (enExample)
HR (1) HRP20151312T1 (enExample)
HU (1) HUE027216T2 (enExample)
PL (1) PL2229185T3 (enExample)
PT (1) PT2229185E (enExample)
SI (1) SI2229185T1 (enExample)
WO (1) WO2009076105A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
ES2804424T3 (es) * 2006-07-11 2021-02-08 Nono Inc Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP6005357B2 (ja) * 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
BRPI1010718A2 (pt) 2009-06-10 2016-03-15 Nono Inc sistemas modelo e regimes de tratamento para tratar doença neurológica.
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2011038397A2 (en) * 2009-09-28 2011-03-31 Duke University Peptide adjuvants, vaccines, and methods of use
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
EP2580233B1 (en) * 2010-06-10 2016-08-10 Indiana University Research And Technology Corporation Materials and method for suppressing inflammatory and neuropathic pain
EP2616094B1 (en) * 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
KR102022116B1 (ko) 2011-06-24 2019-09-18 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9730921B2 (en) 2012-03-27 2017-08-15 Duke University Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
HUE043820T2 (hu) * 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
WO2014150350A1 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
WO2016049280A1 (en) * 2014-09-24 2016-03-31 Memorial Sloan Kettering Cancer Center mTORC1 MODULATION
WO2019061395A1 (zh) * 2017-09-30 2019-04-04 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159418A2 (en) * 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE60026313D1 (de) * 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
AU2002356511A1 (en) * 2001-07-30 2003-04-01 Immunex Corporation T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using
US20060276455A1 (en) * 2003-02-13 2006-12-07 Lindsberg Perttu J Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP2801366A3 (en) * 2004-09-02 2015-04-29 Cognosci, Inc. Improved apo E analogs and methods for their use
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2178549B1 (en) * 2007-07-26 2016-09-14 Revance Therapeutics, Inc. Antimicrobial peptide and compositions thereof
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Similar Documents

Publication Publication Date Title
JP2011506328A5 (enExample)
HRP20151312T1 (hr) Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom
Li et al. Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics
JP2012530060A5 (enExample)
JP2014527040A5 (enExample)
US10046060B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
Lei et al. The novel Nrf2 activator CDDO‐EA attenuates cerebral ischemic injury by promoting microglia/macrophage polarization toward M2 phenotype in mice
JP2014518275A5 (enExample)
Goldsmith et al. Intestinal epithelial cell–derived μ-opioid signaling protects against ischemia reperfusion injury through PI3K Signaling
JP2012176978A5 (enExample)
JP2015057436A5 (enExample)
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
NZ600790A (en) Combination therapy for copd
WO2011047097A3 (en) Inhibition of trem receptor signaling with peptide variants
JP2014516942A5 (enExample)
JP2015522264A5 (enExample)
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
JP2011528334A5 (enExample)
Hill et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study
WO2009047826A2 (en) Pharmaceutical composition comprising sucralphate and mesalazine
Urakov et al. Inflammation, Infiltration, Necrosis, Abscess and Nicolau Syndrome after Injection of Nonsteroidal Anti-inflammatory Drugs: What is the Reason?
JP2011527317A5 (enExample)
CN103585153B (zh) Caesanines D在治疗和预防肾纤维化药物中的应用
Hawley et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: reasons for switching and safety
WO2006043260A3 (en) Orally effective cannabinoid analogs